AI Science Tracker

Sun Yat-sen University Cancer Center

2 discoveries from 2026

Discoveries

Prospective multicentre study combines EV protein biomarkers and machine learning for preclinical oesophageal cancer detection

The BarFlare assay and an interpretable multi-criteria decision-making classification-fusion machine-learning framework combined extracellular-vesicle SCC and MMP13 biomarkers with clinical factors. The model was evaluated in prospective multicentre diagnostic cohorts and two population cohorts; the longitudinal cohort contained baseline samples from 30 people who later developed oesophageal squamous cell carcinoma, with a reported median lead time of 34.9 months and AUC 0.864. The paper also reports external diagnostic validation in two cohorts.

Technology: Multi-criteria decision-making Classification Fusion (MCF) machine-learning framework; 289 candidate feature-selector/classifier pairs were compared and three base models fused

Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: prospective or independent check
  • Tested: The BarFlare assay and an interpretable multi-criteria decision-making classification-fusion machine-learning framework combined extracellular-vesicle SCC and MMP13 biomarkers with clinical factors.
  • Still unknown: This is a prospective observational diagnostic study, not an intervention trial or proof that screening improves outcomes. The longitudinal preclinical cohort had 30 incident cases and matched controls; performance estimates require external replication in larger populations. The source reports an association and lead time, not guaranteed individual prediction. Primary publisher full text and abstract checked; no independent replication assessed.
  • AI role: The MCF framework integrated newly identified EV biomarkers with clinical variables, selected and fused machine-learning classifiers, and produced the risk score evaluated in diagnostic and prospective population cohorts. BarFlare is the high-sensitivity EV assay platform, not the AI model.

Evidence sources: https://isevjournals.onlinelibrary.wiley.com/doi/10.1002/jev2.70246

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 3/5 · Validation 4/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Deep-learning histopathology identifies tertiary lymphoid structure features linked to stage II colorectal cancer relapse

SurvFinder analyzed 6,950 H&E slides from 1,604 stage II colorectal cancer patients across four cohorts and identified tertiary lymphoid structures (TLSs) as prognostic tissue features. Its multi-view model integrated TLS morphology and spatial location; explainable analysis highlighted TLS maturity and position near the tumor periphery as features associated with relapse-free survival and adjuvant-chemotherapy outcome patterns across the retrospective datasets.

Technology: SurvFinder, a multi-component deep-learning pipeline: WSINet for prognosis-associated tissue features, SegNet for TLS segmentation/subtyping, and MVNet for multi-view risk prediction

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: SurvFinder analyzed 6,950 H&E slides from 1,604 stage II colorectal cancer patients across four cohorts and identified tertiary lymphoid structures (TLSs) as prognostic tissue features.
  • Still unknown: This was a retrospective analysis of patients enrolled in 2012–2018; results do not establish prospective clinical utility. Associations between predicted risk, TLS features and adjuvant-chemotherapy outcomes are observational and do not prove treatment benefit or that TLS features causally determine relapse. The authors identify absence of prospective validation and real-world deployment as limitations.
  • AI role: Deep learning autonomously identified prognosis-associated tissue features in whole-slide images, segmented and subtyped TLSs, and integrated morphological and spatial features for risk prediction. Explainable-AI attribution identified TLS location near the tumor margin and TLS maturity state as important prognostic features.

Evidence sources: https://pubmed.ncbi.nlm.nih.gov/41532433/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.